For over 20 years Dr. Scott Rocklage has been involved with companies on the cutting-edge of the latest biomedical technologies and treatments. Currently he is managing partner of 5AM Ventures, a venture capital firm which provides funding for companies involved in early stage life science related projects. Dr. Rocklage is constantly studying the latest ideas and concepts in life science and working to help physicians and scientists transform their ideas into effective medicines for treating the most devastating medical conditions of our time.
Dr. Rocklage has been in the forefront of medical and scientific research for many years. While working on his Ph.D. in Chemistry at the Massachusetts Institute of Technology, he conducted research in the lab of Richard R. Schrock, the 2005 Nobel Prize winner in Chemistry. And the latest scientific developments still excite Scott Rocklage. Currently the biomedical developments in cancer prevention, diagnosis and treatment have captured his interest. He is excited by the potential of the advances being made in targeted techniques and technologies aimed at specific genotypes and mutations in cancer patients as innovative, new ways to destroy cancerous cells and improve treatment outcomes.
Since getting his undergraduate degree in chemistry from UC Berkley and his Ph.D. from MIT, Dr. Rocklage has been deeply involved in medical research and the healthcare industry. He helped get U.S. FDA approval for the groundbreaking new drugs Teslascan®, Cubicin® and Omniscan™. He has also played a seminal role in getting clinical trials started for six drug candidates. Dr. Rocklage has also held leadership positions in a large number of biotech and biomedical companies and has provided them with the guidance and support they need to succeed.
Dr. Scott Rocklage has held executive leadership or directorial board positions with Cubist Pharmaceuticals, Nycomed Salutar and Nycomed Interventional. He also worked with Salutar and Catalytica doing research and development. While serving as 5AM Ventures’ managing partner and working with their portfolio management team, Dr. Rocklage is also on the directorial boards of WaveRx, Pulmatrix, Variation, Semprus, Achaogen, Relypsa, Ilypsa and Miikana. He’s also on the board of associates of the Whitehead Institute.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.